Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Largest Clinical Trials Database of Amyotrophic Lateral Sclerosis Created to Find a Cure

By BiotechDaily International staff writers
Posted on 10 Dec 2012
The largest open access ALS clinical trial database has been created to accelerate the finding and cure for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

PRO-ACT (Pooled Resource Open-Access ALS Clinical Trials) is an effective application that merges data from existing privately and publicly conducted ALS clinical trials and makes these data widely available for research, creating an instrumental resource for accelerating discovery in the field of ALS. Prize4Life (Cambridge, MA, USA), a nonprofit organization whose goal is to hasten the discovery of treatments and a cure for ALS, and the Neurological Clinical Research Institute (NCRI; Boston, MA, USA) at Massachusetts General Hospital created the PRO-ACT database with funding from the ALS Therapy Alliance and in partnership with the Northeast ALS Consortium (NEALS).

Substantial data donations came from pharmaceutical companies including Sanofi, Novartis, Teva Pharmaceutical Industries, and Regeneron Pharmaceuticals, as well as academic institutions worldwide. “With the creation of the PRO-ACT database, Prize4Life and the NCRI have given companies like ours cause to rethink priorities and strategies regarding ALS, since the abundant clinical and patient data contained within it will help us develop viable phase II and phase III treatments for ALS,” said Dr. Doug Kerr, Biogen Idec’s (Zug, Switzerland) medical director, neurodegeneration clinical development.

PRO-ACT contains more than 8,500 fully deidentified unique clinical trial patient records, including medical history, demographic, lab, functional scores, and other data components. The dataset currently includes both placebo, and in most cases, treatment-arm data from 18 late stage (phase II/III) ALS clinical trials, resulting in over eight million longitudinally gathered data points. Prize4Life and the NCRI initiated this project with the conviction that making ALS clinical trial data globally available would catalyze more ALS discoveries to occur faster.

“The vision for PRO-ACT is that the ALS community and other interested researchers around the world will have access to enough data to answer previously unanswerable basic questions, such as, how much does ALS differ between men and women,” said Prize4Life’s chief scientific officer, Dr. Melanie Leitner. “PRO-ACT will also help to answer more complicated questions, such as, can we identify subgroups of people who may actually have responded to treatment in any of the completed trials.”

ALS, a fatal disease, is tough to predict. Although the average life expectancy of an ALS patient is approximately three years, some individuals live for decades, whereas others die within months. This absence of probability makes the design of clinical trials for possible new treatments a long, expensive, and complicated process. ALS research will advance when researchers are able to identify the patterns hidden in the millions of data points in PRO-ACT, which were collected from thousands of ALS patients involved in earlier clinical trials.

“As clinicians who see ALS patients every day, we recognize the huge potential impact of having access to vastly more patient data than anyone has ever had before. As just one example, being able to identify factors that determine the rate of progression in people with ALS will allow us to improve clinical trial design,” said Dr. Merit Cudkowicz, director of the NCRI, neurology chief at Massachusetts General Hospital and NEALS co-chair. “Because of PRO-ACT, ALS researchers will be better able to design trials that need fewer participants.”

The findings gathered by use of the PRO-ACT database will benefit more than just the scientific and medical research fields; they will also impact ALS patients and their families potentially by giving them answers to their questions about what to expect following diagnosis.

“When my father was first diagnosed with ALS, one of the things my family and I struggled with the most was the time it took for him to receive a definitive diagnosis amid the ambiguity of the disease,” said Peter Bowen, former Prize4Life board fellow and primary fundraiser for the DREAM-Phil Bowen ALS Prediction Prize4Life Challenge named in honor of his late father, Phil Bowen. “It is my hope that the PRO-ACT database will provide answers which allow doctors to be able to tell an ALS patient and his or her family sooner, rather than later, what the future may hold.”

The PRO-ACT database is freely accessible to the global research community for analysis and downloads online (please see Related Links below).

Prize4Life is a) nonprofit organization that uses powerful incentives to drive innovation. Founded in 2006 by Avi Kremer, who was diagnosed with ALS at the age of 29, Prize4Life encourages and rewards creative approaches that will provide results for ALS patients.

The Neurological Clinical Research Institute (NCRI) at Massachusetts General Hospital accelerates translational research in neurologic disorders through initiating and assessing innovative therapies.

Related Links:

PRO-ACT database
Prize4Life
Neurological Clinical Research Institute



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Diagram illustrates the innovative process that could lead to more effective drugs against influenza infection (Photo courtesy of the Hebrew University of Jerusalem).

Researchers Show How the Influenza Virus Blocks Natural Killer Cell Recognition

A team of molecular virologists has described how the influenza virus evolved a defense mechanism to protect it from attack by the immune system's natural killer (NK) cells. The recognition of pathogen-infected... Read more

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.